Array-Based Comparative Genomic Hybridization Identifies Localized DNA Amplifications and Homozygous Deletions in Pancreatic Cancer

• Main Authors: Murali D. Bashyam, Ryan Bair, Young H. Kim, Pei Wang, Tina Hernandez-Boussard, Collins A. Karikari, Robert Tibshirani, Anirban Maitra, Jonathan R. Pollack
• Format: Article
• Language: English
• Published: Elsevier 2005-06-01
• Series: Neoplasia: An International Journal for Oncology Research
• Subjects: Pancreatic cancer; array CGH; comparative genomic hybridization; expression profiling; DNA amplification
• Online Access: http://www.sciencedirect.com/science/article/pii/S1476558605800764
• ISSN: 1476-5586; 1522-8002

Pancreatic cancer, the fourth leading cause of cancer death in the United States, is frequently associated with the amplification and deletion of specific oncogenes and tumor-suppressor genes (TSGs), respectively. To identify such novel alterations and to discover the underlying genes, we performed comparative genomic hybridization on a set of 22 human pancreatic cancer cell lines, using cDNA microarrays measuring ~ 26,000 human genes (thereby providing an average mapping resolution of <60 kb). To define the subset of amplified and deleted genes with correspondingly altered expression, we also profiled mRNA levels in parallel using the same cDNA microarray platform. In total, we identified 14 high-level amplifications (38–4934 kb in size) and 15 homozygous deletions (46–725 kb). We discovered novel localized amplicons, suggesting previously unrecognized candidate oncogenes at 6p21, 7q21 (SMURF1, TRRAP), 11q22 (BIRC2, BIRC3), 12p12, 14q24 (TGFB3), 17ql2, and 19q13. Likewise, we identified novel polymerase chain reaction-validated homozygous deletions indicating new candidate TSGs at 6q25, 8p23, 8p22 (TUSC3), 9q33 (TNC, TNFSF15),10q22, 10q24 (CHUK), 11p15 (DKK3), 16q23, 18q23, 21q22 (PRDM15, ANKRD3), and Xp1l. Our findings suggest candidate genes and pathways, which may contribute to the development or progression of pancreatic cancer.